Data as of the August 28, 2026 close. Wave Life Sciences (NASDAQ: WVE) is a clinical-stage biotech developing RNA-based medicines on its PRISM platform, with programs in obesity, alpha-1 antitrypsin deficiency, and liver disease.
Baseline Data
| Metric | Value |
| Price | $5.04 (Aug 28, 2026 close, down 2.3%) |
| 52-week range | $5.01 / $21.73 (sitting at the low) |
| Market cap | $993M |
| Enterprise value | $546M |
| Total cash | $490.6M ($368.0M cash + $122.6M short-term investments), Q2 2026 (6/30/26) |
| Debt | $0 interest-bearing debt. The $43.59M “total debt” shown on aggregators is entirely lease liabilities ($40.08M long-term + $3.51M current). The Q2 2026 press release states no loan obligations. |
| Forward P/E | N/A (unprofitable, TTM net loss $202.5M) |
| PEG | N/A |
| Shares out / float | 197.0M / 94.6M |
| Short interest | 16.20M shares, 17.13% of float, short ratio 5.75 days |
| Insider ownership | 0.41% (stockanalysis) vs 15.5% (InsiderInsights). The gap is definitional: InsiderInsights includes 5%+ beneficial owners such as RA Capital and GSK. |
| Institutional ownership | 66.7% to 85.6% depending on source |
| Analyst consensus | Strong Buy, average target $19.06, 16 analysts |
Short interest caveat: neither Nasdaq nor stockanalysis currently exposes a settlement date for WVE, most likely because the Singapore-to-Delaware redomiciliation completed on August 10, 2026 and reset the security record. Treat the 17% figure as approximate and possibly pre-redomiciliation.
Why the Stock Is Here
On March 26, 2026, WVE-007 (INHBE siRNA, obesity) reported six-month Phase 1 data showing 0.9% placebo-adjusted weight loss, up from 0.3% at three months. Visceral fat fell 14.3% and waist circumference 3.3%, with lean mass preserved, but the headline weight number missed expectations badly. The stock roughly halved and has continued to drift lower since, from about $21 to $5.
Cash runway extends into Q3 2028. Q2 2026 results: revenue $2.3M (down from $8.7M), R&D $51.3M, G&A $24.8M, net loss $69.4M. Cash burn is running around $70M per quarter against $490.6M on hand, which is consistent with the stated runway.
Near-Term Catalysts (All H2 2026)
- WVE-007 600 mg SAD cohort Phase 1 data
- WVE-007 Phase 2a multidose in BMI 35-50 (dosing underway), plus combination and post-incretin maintenance trials expected to initiate
- WVE-006 (AATD) 600 mg monthly cohort data, and an FDA meeting on the accelerated approval pathway scheduled for the end of summer 2026
- WVE-008 (PNPLA3) clinical trial application filing
- Investor Day, fall 2026
WVE-N531 (Duchenne muscular dystrophy) and WVE-003 (Huntington’s disease) are both parked pending partnerships.
Insider Activity
The one item that matters: RA Capital (DIR, BO) bought $54.6M on the open market, 8,772,496 shares at $6.06 to $6.50, over March 26-30, 2026, immediately into the obesity-data crash. That raised its position 48.2% to 26,975,504 shares. This is conviction buying by an insider-designated fund, though the stock now trades roughly 17% below their average entry.
GSK’s $27.9M purchase of 1,470,000 shares at exactly $19.00 on December 11, 2025 is collaboration-linked equity at a fixed price, not a market signal.
August 2026 director activity is routine. Rawcliffe, Wagner, Takanashi, and Tan each sold small amounts under 10b5-1 plans (code AS, $2.6K to $67K) at $5.29 to $6.01. Wagner’s 7,000-share award on August 11, followed the same day by a 7,000-share sale, is an award-and-sell, not directional. There is nothing bearish to read into it.
The Read
Heavy short interest at 17% of float alongside a large insider-affiliated fund adding aggressively is a genuine two-sided setup, not a one-way signal. The stock is priced at roughly 2x net cash, with the entire obesity thesis discounted out.
The binary is the H2 2026 WVE-007 Phase 2a and 600 mg data. Management’s argument is that higher-BMI patients and higher doses fix the weight-loss number, and that is unproven. The AATD accelerated-approval meeting with the FDA is the underappreciated second leg.
The $19 consensus target looks stale relative to the March data. Several firms have cut into a $12 to $26 range, and no evidence was found supporting the average beyond that lag.
Disclaimer
This is my own research, done with my own money on the line, and posted here mostly so I can find it again later. I am not a financial advisor and nothing above is a recommendation to buy or sell anything. Numbers get stale fast, especially with a clinical-stage biotech, and I make mistakes. Go check the filings and the primary sources yourself before you do anything with this.